Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer
Baghdad Journal of Biochemistry and Applied Biological Sciences · 2020
DOI: 10.47419/bjbabs.v1i01.28 ↗Kurz gefasst
Fachartikel in der Zeitschrift Baghdad Journal of Biochemistry and Applied Biological Sciences, 2020. Verfasst von Amal A. Hussein und 2 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Prostate cancer is one of the most common cancers in men, worldwide. Many markers are suggested for prostate cancer with different specificity and sensitivity.
Objectives
This study is aimed is to examine the possible utility of prostate-specific antigen indices as markers of prostate cancer.
Methods
A case-control study was conducted in the Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq from July 2018 till March 2019, includes 84 subjects divided into three groups: twenty-four patients with prostate cancer (PCA), thirty patients with benign prostatic hyperplasia (BPH) and thirty healthy subjects as a control group were examined in this study. Blood samples from all participants were collected, and before obtaining a prostatic biopsy from patients. Serum prostate-specific antigen (PSA) and free prostate-specific antigen (fPSA) levels were quantified by the ELISA technique.
Results
PSA cut-off value was found to be more than 9.57 ng/ml for PCA patients, values range between 3.17–9.57 ng/ml for BPH patients and cut-off value for control was found to be less than 3.17 ng/ml, while serum (fPSA/PSA)% cut-off value was less than 11.1% for PCA patients, values range between 11.1%—31 % for BPH patients, and cut-off value was greater than 31% for the control group.
Conclusion
There is a highly significant difference in serum PSA levels and (fPSA/PSA)% between the PCA and control groups. Body mass index showed an inverse association with the risk of prostate cancer.
Zitieren
APA
Hussein, A. A., Baban, R., & Hussein, A. (2020). Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Baghdad Journal of Biochemistry and Applied Biological Sciences. https://doi.org/10.47419/bjbabs.v1i01.28
Vancouver
Hussein AA, Baban R, Hussein A. Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Baghdad Journal of Biochemistry and Applied Biological Sciences. 2020. doi:10.47419/bjbabs.v1i01.28
BibTeX
@article{Hussein2020,
author = {Hussein, Amal A. and Baban, Rayah and Hussein, Alaa},
title = {Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer},
journal = {Baghdad Journal of Biochemistry and Applied Biological Sciences},
year = {2020},
doi = {10.47419/bjbabs.v1i01.28}
}
EUVIMED